Skye Bioscience, Inc. Common Stock (SKYE) financials · $25.0M cap
Lician Pro · $19.99/mo or $149/yrCompare AAPL vs MSFT
Skye Bioscience, Inc. Common Stock (SKYE) $25.0M cap.
| Line | FY2025 | FY2024 | Pro (2 older periods with Lician Pro) |
|---|---|---|---|
| Operating Income | −$58.16M | −$30.19M | |
| Net Income | −$55.92M | −$26.57M | |
| EPS (Diluted) | −$1.41 | −$0.73 | |
| Unlock 5 years of statements: Lician Pro $149/yr | |||
| Line | FY2025 | FY2024 | Pro (3 older periods with Lician Pro) |
|---|---|---|---|
| Total Assets | $28.31M | $72.76M | |
| Current Assets | $27.09M | $70.83M | |
| Cash & Equivalents | $5.88M | $68.42M | |
| PP&E | $898.93K | $1.43M | |
| Total Liabilities | $8.29M | $4.61M | |
| Current Liabilities | $8.21M | $4.34M | |
| Shareholders' Equity | $20.02M | $68.15M | |
| Retained Earnings | −$186.87M | −$130.95M |
| Line | FY2025 | FY2024 | Pro (3 older periods with Lician Pro) |
|---|---|---|---|
| Operating Cash Flow | −$43.06M | −$25.24M | |
| CapEx | $6.31K | $1.60M | |
| Investing Cash Flow | −$19.50M | −$245.62K | |
| Financing Cash Flow | $29.57K | $83.56M | |
| Net Change in Cash | −$62.53M | $58.08M | |
| Free Cash Flow | −$43.07M | −$26.84M |
Source: Company filings with the SEC (EDGAR) · Latest period FY2025
FAQ
What is SKYE P/E and revenue?
Skye Bioscience, Inc. Common Stock (SKYE) $25.0M cap.
What is SKYE revenue?
SKYE income-statement cache has no revenue figure yet.
Is SKYE profitable?
Skye Bioscience, Inc. Common Stock last cached net income is -$55.9M (FY2025).
What are SKYE total assets?
Skye Bioscience, Inc. Common Stock last cached total assets are $28.3M (FY2025).
What is SKYE free cash flow?
Skye Bioscience, Inc. Common Stock last cached free cash flow is -$43.1M (FY2025).
Not investment advice. Figures as reported in company filings, not a live feed.